First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Advanced Solid TumorsHNSCCSCLCNSCLCTNBC - Triple-Negative Breast CancerCRC
Interventions
DRUG

TUB-030

A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle

Trial Locations (13)

11766

RECRUITING

Mount Sinai, New York

33136

RECRUITING

University of Miami, Miami

43210

RECRUITING

Ohio State University, Columbus

44195

RECRUITING

Cleveland Clinic, Cleveland

55905

RECRUITING

Mayo Clinic, Rochester

63130

RECRUITING

Washington University, St Louis

75039

RECRUITING

NEXT Oncology - Dallas, Irving

78229

RECRUITING

NEXT Oncology - San Antonio, San Antonio

78758

RECRUITING

NEXT Oncology Austin, Austin

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

06510

RECRUITING

Yale Cancer Center, New Haven

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Unknown

RECRUITING

Princess Margaret, Toronto

All Listed Sponsors
lead

Tubulis GmbH

INDUSTRY